CAMBRIDGE, MA—Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics, Inc. (NASDAQ:), executed a inventory transaction not too long ago, promoting 3,984 shares of widespread inventory. The shares have been bought at a weighted common worth of roughly $0.6901 per share, totaling $2,749. This sale was carried out underneath a pre-arranged Rule 10b5-1 buying and selling plan, primarily to cowl taxes related to the vesting of restricted inventory items.
On October 27, 2024, Henn acquired 12,622 shares of widespread inventory with none financial alternate, as these have been a part of a vesting schedule for beforehand granted restricted inventory items. Following these transactions, Henn now holds 75,885 shares of Seres Therapeutics widespread inventory straight.
In different current information, Seres Therapeutics has been the topic of a number of developments. The corporate’s resolution to promote its VOWST enterprise to Nestlé Well being Science has been authorized by shareholders. This transfer, which incorporates the switch of the primary FDA-approved orally administered microbiome therapeutic, is anticipated to considerably strengthen Seres Therapeutics’ monetary place regardless of a reported web lack of $32.9 million.
JPMorgan has downgraded Seres Therapeutics from Impartial to Underweight, citing unclear progress potential and the absence of fast, clear progress drivers. Nonetheless, TD Cowen maintains a Purchase score on the corporate’s shares, following optimistic information from the Section 1b trial of SER-155 in sufferers present process allogeneic Hematopoietic Stem Cell Transplantation.
Seres Therapeutics’ shareholders have additionally raised considerations over the corporate’s rejection of a takeover bid from Nestlé S.A. and the next sale of the VOWST enterprise. The corporate is getting ready SER-147 for IND readiness by the second half of 2025, concentrating on metabolic ailments. These are current developments from Seres Therapeutics.
InvestingPro Insights
Latest transactions by Seres Therapeutics’ Chief Scientific Officer Matthew R. Henn spotlight the corporate’s ongoing stock-based compensation practices. Whereas these insider actions present some perception into govt compensation, a broader take a look at Seres Therapeutics’ monetary well being reveals extra urgent considerations for buyers.
In response to InvestingPro information, Seres Therapeutics at the moment has a market capitalization of $131.51 million, reflecting its standing as a small-cap biotech firm. The agency’s monetary metrics paint a difficult image, with income for the final twelve months as of Q2 2023 standing at simply $0.37 million, coupled with a staggering income decline of 99.71% over the identical interval.
InvestingPro Suggestions point out that Seres Therapeutics is “shortly burning via money” and “operates with a major debt burden.” These components are significantly regarding for a biotech firm that depends closely on analysis and growth to convey merchandise to market. The corporate’s unfavourable gross revenue margin of -25,214.44% additional underscores the monetary pressure it is underneath.
The inventory’s efficiency has been notably weak, with InvestingPro information exhibiting a 46.08% worth decline over the previous three months. This aligns with one other InvestingPro Tip stating that the “inventory has taken a giant hit during the last week” and has “fared poorly during the last month.”
For buyers searching for a extra complete evaluation, InvestingPro affords 11 extra suggestions that might present beneficial insights into Seres Therapeutics’ funding potential. The following tips, together with real-time metrics, may also help in forming a extra knowledgeable funding resolution within the unstable biotech sector.
This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.
